Aligos Therapeutics, Inc. Operating Income Loss

• Aligos Therapeutics, Inc. showed an increase of +1.3% in Operating Income Loss from 2024 to 2025.
• This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Aligos Therapeutics, Inc.'s Operating Income Loss has declined by 62.8%.
• Historical annual values: Fiscal year 2025: -$87.99 million | Fiscal year 2024: -$89.15 million | Fiscal year 2023: -$88.13 million | Fiscal year 2022: -$97.58 million | Fiscal year 2021: -$128.32 million | Fiscal year 2020: -$97.83 million | Fiscal year 2019: -$54.04 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026